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Abstract
Background: The free b subunit of human chorionic gonad-
otropin (free b-hCG) is an important serum marker for bio-
chemical screening. Its weekly median value varies with
ethnicity. Most of the fluorometers for lanthanide chelates
are designed for the detection of signals from europium
(Eu3q) chelates only.
Methods: We developed a two-site, one-step assay using two
monoclonal antibodies (MAbs) against free b subunit and b
subunit with Eu3q chelates as labels. Using the present assay,
we evaluated 24,634 normal serum samples in Chinese preg-
nant women during 8–20 weeks of gestation.
Results: The detection limit using this assay was -0.05
ng/mL. The within-run and between-run imprecision was
-6.0% and 7.0% using control material. Free b-hCG con-
centrations measured using the current assay in 999 maternal
serum samples correlated well with those obtained by samar-
ium (Sm3q)-labeled DELFIA free hCGb assay (˜rs0.987).
The medians for 8–20 weeks for maternal serum free b-hCG
were higher in the women from mainland China compared
to reports from other countries.
Conclusions: The present assay is suitable for use in bio-
chemical screening of women in mainland China. Our study
on the median concentrations of free b-hCG will help estab-
lish reference values that are specific for ethnic populations
from the Chinese mainland. These will be useful for studying
the importance of ethnic factors in biochemical screening.
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Introduction
As a glycoprotein hormone, there are several forms of human
chorionic gonadotropin (hCG) in human serum (1). The free
b subunit of human chorionic gonadotropin (free b-hCG) is
one of the most important serum markers used in detecting
and monitoring pregnancy during the first and second tri-
mesters (2–6). Measurement of free b-hCG has been report-
ed to improve the performance of screening for Down
syndrome (DS) (2, 6–9). The concentrations of weekly medi-
an values of free b-hCG in pregnancy have been found to
be variable according to race or ethnicity (2, 10, 11).
Many laboratories have developed various immunoassay
formats for detecting free b-hCG (12–16). PerkinElmer has
a commercial kit available (AutoDELFIA hAFP/hCGb Dual
kit and Free hCGb DELFIA) which are CE approved. These
are based on time-resolved fluoroimmunoassay (TRFIA) and
are widely used in measurement of free b-hCG in prenatal
screening (2, 17–19). Pettersson et al. (14) reported a simul-
taneous assay for detection of a-fetoprotein and free b-hCG.
In these assays, samarium (Sm3q) chelates were used to
detect free b-hCG.
In mainland China, three types of fluorometers for detec-
tion of lanthanide chelates are available. These include DR-
M from Guangzhou Darui Antibody Engineering and
Technology Co., Ltd, Any test from Sym-Bio Lifescience
Co., Ltd, and TALENT from Guangzhou Fenghua Bioengi-
neering Co., Ltd. However, these instruments can detect sig-
nals from europium (Eu3q) chelates only, not from Sm3q
chelates that are used for AutoDELFIA hAFP/hCGb Dual
kit and the Free hCGb DELFIA kit. The objective of this
study was to develop and validate a sensitive and specific
assay for the detection of free b-hCG in serum using instru-
ments available and produced in China. Eu3q chelates were
used to label a specific antibody against b-hCG. After free
b-hCG was captured onto the surface of microtitration strips
by anti-free b-hCG antibody, the bound fractions of the label
were dissociated in a fluorescence enhancement solution, fol-
lowed by detection with a fluorometer.
Previous studies have shown that the concentration of
serum markers in different populations might vary and affect
the accuracy of prenatal screening (2, 11). Although several
studies have determined differences in free b-hCG concen-
trations in different populations, the weekly median values
determined in these studies are based on small numbers of
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cases. The weekly median values of free b-hCG in the sec-
ond trimester of pregnancy for women from mainland China
have never been determined. To obtain more accurate weekly
median values for this population, 24,634 serum samples
were collected from mainland Chinese women during
8–20 weeks of gestation. Free hCG concentrations were
measured using a TRFIA method developed by us. Weekly
median values of free b-hCG in these Chinese women were
established.
Materials and methods
Materials
Monoclonal antibodies (MAbs) were used for capture and detection.
In the two-site assay for free b-hCG, the capture antibody recog-
nizes an epitope present only on the free subunit. For detection,
another MAb was used to recognize the b subunit of hCG. MAbs
5004, 5006, 5008 and 5012 were obtained from Medix Biochemica.
MAb E82583M was obtained from Meridian Life Science, Inc.
MAb ab36212 was obtained from abCAM, Inc. All MAbs were of
the IgG1 class.
Highly purified b-hCG standard was obtained from Meridian Life
Science, Inc. The calibrators were calibrated against WHO IRP75/
551 for b-hCG (WHO International Laboratory for Biological Stan-
dards, Statens Serum Institute). One international unit (1 IU) of the
b-hCG standard corresponds to 1 mg. The controls were Lyphochek
Maternal Serum Controls and obtained from Bio-Rad Laboratories,
Inc. (Hercules, CA, USA).
DELFIA Eu-Labeling kits were obtained from PerkinElmer Life
and Analytical Sciences, Inc (PerkinElmer, Waltham, MA, USA).
Sephadex G-50 was obtained from Amersham Pharmacia Biotech
(Piscataway, USA).
The standard diluent was composed of 50 mmol/L Tris-HCl buf-
fer, pH 7.8, 8.5 g/L NaCl, 1.5% bovine serum albumin (BSA),
0.01% Procline 300 and 0.01% Tween 20. The assay buffer con-
sisted of 50 mmol/L Tris-HCl buffer, pH 7.8, 8.5 g/L NaCl, 0.2%
BSA, 0.01% Procline 300, 0.05% bovine globulin, 0.01% Tween 20
and 0.02% diethylene triamine penta-acetic acid.
The DELFIA Free hCGb kits (A097-101) and enhancement solu-
tion used to develop the fluorescence were also from PerkinElmer.
The serum specimens were selected from normal pregnancies, and
ranged from gestational week 8–20. Samples were obtained from
Guangdong Women and Children Hospital and Health Institute of
China. Polystyrene microtiter strips were purchased from Labsys-
tems Oy (Helsinki, Finland). The study was approved by the Ethical
Committee of the Southern Medical University, and it complies with
current ethical considerations.
Instruments
For spectral analysis of the fluorescent chelates, a 1420 Multilabel
Counter (Victor3TM) from PerkinElmer was used with filters for
Eu3q (613 nm) and Sm3q (643 nm).
Immobilization of capture antibody
Polystyrene microtiter strips were coated with capture antibody
using physical adsorption. One hundred and fifty mL of 50
mmol/L sodium carbonate buffer, pH 9.6, containing 3 mg of puri-
fied antibody per microliter, was added to each well and incubated
at 308C for 4 h, followed by 48C overnight. The strips were washed
twice and incubated further overnight at 48C with 200 mL blocking
solution (1 g BSA in 50 mmol/L Tris-HCl plus 30 g of trehalose
plus 0.05% Procline 300). The blocking solution was discarded and
strips were packed in vacuum foil bags containing a humidifier, and
stored at 48C until use.
Labeling of antibodies with Eu3H chelates
Before labeling, the antibodies were filtered, desalted, and concen-
trated through a Microcon Centrifugal Filter Device (YM-50). This
resulted in a final concentration of ;2 mg/mL. For labeling, 1 mg
of protein, 0.2 mg of Eu3q-DTTA wN1-(p-isothiocyanatobenzyl)-di-
ethylene-triamine-N1,N2,N3,N4-tetraacetate chelated with Eu3qx was
added, mixed gently and incubated overnight at 258C. Free chelates
were separated from labeled proteins using gel filtration on a Sepha-
dex G-50 column (1.5=40 cm).
Antibody selection
According to sandwich assay, six kinds of MAbs against the free
subunit (5012, E82583M and ab36212) and against the b subunit
(5004, 5006 and 5008) were tested in pairs, with each antibody
being used as a capture or detection antibody. A one-step sandwich
assay format was used together with a 200-ng/mL b-hCG and a
blank solution.
Procedure of the free b-hCG-TRFIA
Twenty-five mL of standard and samples added into each well of
coated microtitration strips, followed by 100 mL of assay buffer
containing 20 ng Eu3q-labeled detection antibodies. The strips were
incubated at room temperature (RT) with continuous shaking. After
1 h, the strips were washed 6 times. Two hundred mL of enhance-
ment solution (cat: B118-100) was then added to each well and the
strips were incubated at RT for 5 min with slow shaking. Finally,
the fluorescence of each well was measured.
Methods for comparison: free b-hCG Eu3H-labeled
assay vs. Sm3H-labeled assay
Nine hundred and ninety-nine maternal serum samples from 8 to
20 weeks gestation were collected. Free b-hCG concentrations were
measured using the commercial Sm3q-labeled free hCGb DELFIA
assay, and the current Eu3q-labeled free b-hCG-TRFIA. The two
immunoassays were performed simultaneously.
The detection of 8–20 weekly median values
Twenty four thousand six hundred and thirty-four serum samples
from maternal screening programs in mainland China during
2006–2007 were measured. Only normal singleton pregnancies
were selected. The samples were collected during 8–20 weeks of
gestation. Gestational age was based on the last menstrual period
(LMP). Lyphochek Maternal Serum Control, levels 1, 2, 3, were
analyzed in each assay. Control results met the laboratory criteria
for acceptability. Medians and means for serum free b-hCG during
different gestational weeks were calculated. The data were convert-
ed to multiples of the median (MoM) for normal pregnancies at the
relevant gestational age with our established weekly median values.
Statistical methods
Deming regression was performed with the Analyse-it add-in for
Microsoft Excel (version 2.12; Analyse-it Software Ltd, Leeds,
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Figure 1 Dilution curves for free b-hCG concentrations based on
five serum samples using the Eu3q-labeled TRFIA (2- to 32-fold
dilution).
Table 1 Cross-reactivity of various hormones using Eu3q-labeled
TRFIA.
Hormone Concentration, IU/L Free b-hCG
concentration,
ng/mL
LH 300 -0.05
FSH 200 -0.05
TSH 0.30 -0.05
hCG 2000 -1.5
Figure 2 Calibration curve () and corresponding within-assay
imprecision (j) profile for free b-hCG.
The background fluorescence of ;1938 CPS has been subtracted.
Each point is based on ten replicates and the standard deviations of
repeated points were 0.11, 0.33, 0.76, 2.30 and 4.57 ng/mL,
respectively.
UK). Other statistical analyses were performed using SPSS software
(version 13.0, SPSS Inc, Chicago, IL, USA). A p-value of -0.05
was considered for statistical significance.
Results
Best antibody pair
Antibody selection was based on the results of antibody com-
bination studies. A good pair should give lower detection
limits, a better linear dose-response signal, and lower cross-
reactivity. Our results from six MAbs clones showed that the
best antibody pair contained 5012 (against the free b sub-
unit) as the capture antibody and 5006 (against the b subunit)
as the detection antibody (data not shown).
Kinetics, dilution and specificity
Standards and samples (including six maternal serum sam-
ples) were incubated for 0.5, 1, 2, 3 h at RT. For standards
and serum samples, equilibrium was reached in 1 h. The
results showed that a 1-h incubation at RT was sufficient to
give more than 85% of the maximum fluorescence intensity;
longer incubation times did not improve the sensitivity. Par-
allel analysis was performed with five serum samples diluted
serially from 1/2 to 1/32 with assay buffer. As shown in
Figure 1, all five samples diluted linearly. We also tested the
specificity of TRFIA by measuring cross-reactivity of the
present assay against luteinizing hormone (LH), follicle stim-
ulating hormone (FSH), hCG and thyroid stimulating hor-
mone (TSH). The results indicated that this assay has a very
low cross-reactivity against LH, FSH, TSH and hCG (Table
1).
Calibration curves, assay range, detection limit
and imprecision
A typical log calibration curve was linear in the range of
3–200 ng/mL for b-hCG (Figure 2, each point is based on
ten replicates). Linear regression analysis showed a slope
(SD) of 0.9181 (0.0078), a y-intercept of 4.5196 (0.0124)
ng/mL, r2s0.9998 and a SyNx value of 0.0115 ng/mL. The
highest fluorescence intensity for 200 ng/mL b-hCG was
;4,300,000 counts per second (CPS). No hook effect was
observed within the linear range. The detection limit of this
assay was -0.05 ng/mL, corresponding to a minimum
detectable dose of 1.5 pg/mL per well. The detection limit
was defined as the concentration corresponding to the back-
ground counts plus 2 SD (ns20). The within-run impreci-
sion (ns10) of standards was between 2.2% and 3.5%.
Within- and between-run assay variation was determined
using three levels of maternal serum controls and the same
batch of reagents on different days. The results are summa-
rized in Table 2. The intra- and inter-assay coefficients of
variation (CV) ranged from 4.2% to 5.2% and 3.4% to 6.2%,
respectively.
Comparison of methods
We measured free b-hCG concentrations in 999 first or sec-
ond trimester specimens using both the DELFIA Free hCGb
assay and the current free b-hCG-TRFIA. These data were
compared using Deming regression wslope (95% CI), 1.0117
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Table 2 Intra- and inter-assay coefficients of variation (CV) using the Eu3q-labeled TRFIA for measuring free b-hCG.
Serum control Free b-hCG, Intra-assay Inter-assay
ng/mL CV (%, ns35) CV (%, ns68)
39,061 20.0 5.2 6.2
39,062 72.9 5.3 4.5
39,063 122.0 4.2 3.4
Figure 3 Comparison of free b-hCG concentrations using the
present TRFIA and the DELFIA free hCGb kit measured in 999
maternal serum samples.
Table 3 Value of serum free b-hCG during different weeks of gestation.
Gestational Number of Free b-hCG, ng/mL Free b-hCG, ng/mL 5th Percentile 95th Percentile
week samples Medians Mean
(raw data)
8 52 110.0 127.88 32.76 301.54
9 503 109.0 116.08 37.22 228.60
10 704 83.5 97.29 26.53 228.00
11 1095 65.7 78.68 21.68 183.20
12 1626 58.1 69.78 18.60 161.00
13 2276 47.2 58.63 16.09 139.00
14 1645 30.9 36.28 11.93 75.65
15 2378 22.8 26.84 9.35 54.81
16 3033 17.7 20.73 7.04 43.63
17 3614 13.8 16.55 5.66 34.75
18 3141 11.9 14.00 28.10 1.18
19 2545 10.8 12.34 24.30 1.14
20 2022 9.44 11.06 22.69 1.17
(0.9897–1.0337); y-intercept (95% CI), –2.4761 (–2.8986 to
–2.0535) ng/mL; SyNx, 4.8055 ng/mLx. The two assays
showed a correlation coefficient of 0.987 (p-0.001) (Figure
3).
Establishing weekly median values in normal
singleton pregnancies
By measuring 24,634 samples from mainland Chinese wom-
en with the assay we established, we determined the weekly
median values for free b-hCG (Table 3). Free b-hCG con-
centrations at different gestational weeks did not fit a Gaus-
sian distribution. The median values decreased with the
increase in gestational week. The average age of women in
the maternal serum screening program was 28.05 years.
Discussion
By combining two MAbs against the free b subunit and b
subunit of hCG, and using Eu3q as the probe for signal
detection, we developed an immunofluorometric assay for
free b-hCG with high specificity, very high sensitivity, good
reproducibility and short incubation time. Pre-dilution of the
sample is not required and measurement of free b-hCG is
easy. The analytical performance of the present assay was
acceptable and 100 patient samples could be analyzed in
90 min. The fluorescent Eu3q chelates had high quantum
yields. However, the Sm3q chelates had lower fluorescence
intensity (14, 20, 21). Thus, the signal intensity of our assay
with Eu3q was about 60 times higher than the DELFIA Free
hCGb kit. The sensitivity of our assay was -0.05 ng/mL;
much lower than that of the DELFIA Free hCGb (below
0.2 ng/mL, from its user manual) and the method by Pet-
tersson et al. (below 0.2 mg/L) (14). The concentrations of
free b-hCG measured in this study showed good agreement
with the DELFIA Free hCGb method from PerkinElmer.
Thus, our assay could take the place of the Sm3q-labeling
methods for detection of free b-hCG.
As mentioned previously, current fluorometers for lantha-
nide chelates made in China can detect signals from Eu3q
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chelates only, and not Sm3q. Therefore, our assay using
Eu3q chelates is more suitable for measurement of free b-
hCG in mainland China, which should promote prenatal
screening in this area.
The median concentrations of free b-hCG were influenced
by the ethnic origin of the woman. Kagan et al. (2) described
a 12% increase in free b-hCG in women of Afro-Caribbean
origin compared with Caucasians. Leung et al. (11) reported
that Chinese had significantly higher maternal serum free b-
hCG concentrations and pregnancy associated plasma pro-
tein-A (PAPP-A), measured in 943 women during the first
trimester of pregnancy. Our study was based on 24,634 sam-
ples from women from mainland China. We confirmed the
difference due to race and showed that median concentra-
tions of serum free b-hCG were higher in Chinese compared
with other groups. In our study, the free b-hCG median con-
centrations in Chinese were 27%–68% higher than those pro-
vided with the DELFIA Free hCGb kit, 39%–124% higher
than the results by Krantz et al. (22), 35%–68% higher than
those reported by Spencer (23) and 20%–44% higher than
results from Pettersson et al. (14). Our study showed that
free b-hCG median concentrations in Chinese were higher
than found in other studies. In mainland China, PRISCA
(Siemens) and 2T-Risks (3) (PerkinElmer) are most widely
used for risk assessment. Failure to take into account ethnic
differences in Chinese women would result in overestimation
of the true risk of trisomy 21, and underestimation of the
true risk of trisomy 18. Therefore, our study provides ref-
erence data for adjusting free b-hCG medians for biochem-
ical screening in women from mainland China. In addition,
our study should attract interest with respect to the effects
of ethnic differences on biochemical screening.
In conclusion, the present TRFIA, specific for free b-hCG,
provides high sensitivity. This assay is more versatile for
meeting the needs of women from mainland China. Our
study on the median concentrations of free b-hCG will help
to establish reference values specific for the ethnic popula-
tion of mainland China, and is useful for studying the impor-
tance of ethnicity on biochemical screening.
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